Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scalp | 1 | 2024 | 43 | 0.830 |
Why?
|
| Brachytherapy | 2 | 2020 | 50 | 0.820 |
Why?
|
| SEER Program | 5 | 2020 | 105 | 0.770 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 302 | 0.770 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2025 | 177 | 0.770 |
Why?
|
| Glioblastoma | 1 | 2022 | 89 | 0.700 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2020 | 7 | 0.650 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 398 | 0.630 |
Why?
|
| Urethral Neoplasms | 1 | 2019 | 6 | 0.630 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2019 | 34 | 0.620 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2018 | 14 | 0.590 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 643 | 0.580 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 403 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 208 | 0.500 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 641 | 0.400 |
Why?
|
| Survival Rate | 3 | 2020 | 944 | 0.390 |
Why?
|
| Aged | 7 | 2025 | 10242 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1203 | 0.340 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 3449 | 0.340 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 65 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2022 | 485 | 0.320 |
Why?
|
| Survival Analysis | 2 | 2022 | 656 | 0.310 |
Why?
|
| United States | 5 | 2024 | 5215 | 0.290 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 768 | 0.270 |
Why?
|
| Humans | 13 | 2025 | 52441 | 0.250 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6694 | 0.240 |
Why?
|
| Cranial Irradiation | 1 | 2025 | 24 | 0.230 |
Why?
|
| Middle Aged | 5 | 2024 | 13133 | 0.230 |
Why?
|
| Adult | 5 | 2024 | 14205 | 0.220 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2024 | 12 | 0.210 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2024 | 35 | 0.210 |
Why?
|
| Radiation Oncology | 1 | 2023 | 26 | 0.210 |
Why?
|
| Male | 7 | 2025 | 26874 | 0.190 |
Why?
|
| Female | 7 | 2025 | 28277 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2022 | 136 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 289 | 0.170 |
Why?
|
| Medicare | 1 | 2022 | 281 | 0.170 |
Why?
|
| Vesiculovirus | 1 | 2020 | 6 | 0.160 |
Why?
|
| Industry | 1 | 2020 | 16 | 0.160 |
Why?
|
| Patents as Topic | 1 | 2020 | 10 | 0.160 |
Why?
|
| Inventions | 1 | 2020 | 9 | 0.160 |
Why?
|
| Interferon-beta | 1 | 2020 | 33 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 639 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 461 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2020 | 109 | 0.150 |
Why?
|
| Propensity Score | 1 | 2020 | 160 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 446 | 0.150 |
Why?
|
| Mastectomy | 1 | 2020 | 145 | 0.150 |
Why?
|
| Universities | 1 | 2020 | 174 | 0.150 |
Why?
|
| Florida | 1 | 2018 | 71 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2023 | 438 | 0.140 |
Why?
|
| Cohort Studies | 1 | 2020 | 1576 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5508 | 0.100 |
Why?
|
| Prognosis | 1 | 2018 | 2100 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2294 | 0.100 |
Why?
|
| Young Adult | 1 | 2018 | 4346 | 0.070 |
Why?
|
| Adolescent | 1 | 2018 | 6713 | 0.070 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2024 | 9 | 0.050 |
Why?
|
| Faculty | 1 | 2023 | 72 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 256 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 227 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2024 | 184 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 243 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 218 | 0.040 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 19 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 218 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 140 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 128 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 165 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 2433 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1013 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 853 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1429 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 5899 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 13485 | 0.010 |
Why?
|